Zydus Cadila receives approval for Baclofen Tablets

Zydus Cadila has received the final USDFA approval for Baclofen Tablets, 10mg and 20mg. The shares of the company, however fell intraday.

The United States Food and Drug Administration has granted Zydus Cadila to manufacture Baclofen Tablets at the group’s formulations manufacturing facility at Baddi, Himachal Pradesh. Baclofen works by helping to relax the muscles, thus treating muscle spasms that are generally caused by certain conditions such as multiple sclerosis or spinal cord injury.

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies.

On Tuesday, the shares of Cadila Healthcare opened at Rs. 356 per share as against Monday’s close of Rs 353.25. At 15:15 hours, the shares of the company were trading at Rs 344.55, down by 2.46 per cent or by 8.70 points. The intraday high was Rs. 356.90 and intraday low was Rs. 342.90 per share on the BSE. Its 52-week high was Rs. 456.10 and 52-week low was Rs. 330.65 per share on the BSE.

Meanwhile, the BSE Sensex was at 35,509.39 level, up by 0.44 per cent and the Nifty50 was at 10,682.75, up by 0.51 per cent.